Alicia describes how
genetic and
biomarker testing has significantly impacted the treatment of her ovarian cancer because the results have opened doors for
clinical trial participation. She qualified for a clinical trial focused on
BRCA-negative,
HRD-positive patients. Alicia shares that her ongoing experience in the trial has been great and that she has a lot of confidence in it, as her cancer has not recurred in 4 years.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about ovarian cancer which will help other patients, caregivers and families.
-
Share with family and friends: